DURHAM — Kincell Bio and Cellipont Bioservices completed a merger that combines their cell-therapy development and manufacturing operations under a new company, Kincellis Advanced Therapies.

The companies announced the completed transaction Sept. 17. Kincell’s announcement describes Kincellis as a U.S.-based contract development and manufacturing organization supporting advanced therapies from early development through commercial supply.

The combined company operates about 140,000 square feet across Gainesville, Florida; Durham’s Research Triangle Park; and The Woodlands, Texas. Its network includes 16 operational, qualified manufacturing suites and more than 200 employees across the three locations. The companies said they have released more than 150 good-manufacturing-practice batches for clients and are supporting 10 investigational-new-drug filings this year.

The North Carolina operation at 20 T.W. Alexander Drive emphasizes pivotal-stage and commercial manufacturing, while the Gainesville facility focuses on early development and clinical supply, according to Kincell’s facilities overview. A CBRE property listing identifies the T.W. Alexander Drive address as Durham.

Darren Head is chief executive officer of Kincellis, and Larry Pitcher is president. Mark Bamforth is executive chair of the board. The company said the transaction’s equity financing was led by NewSpring Capital, with support from Kineticos Life Sciences, HealthQuest Capital and Great Point Partners. J.P. Morgan provided a debt facility, and William Blair advised Cellipont.

Financial terms were not disclosed. The announcement did not identify North Carolina-specific job changes, layoffs, a facility expansion or a production interruption. It said the combined network is intended to give customers more capacity and continuity as therapies move from development toward commercial supply.

Sources